Search Results

648 Results for "insitro inc.rss".

Sort By

ALS

BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line

Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.

October 15, 2025
·
1 min read
·
Tristan Manalac
Press Releases

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform

October 15, 2025
·
4 min read
Press Releases

insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026
·
1 min read
Layoffs

Insitro Cuts 22% of Workforce, Extending Runway Into 2027

Insitro’s layoffs affect about 65 employees as the AI-focused biotech looks to advance its pipeline in metabolic disease and neuroscience.

May 9, 2025
·
2 min read
·
Angela Gabriel
Press Releases

insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects

February 3, 2026
·
4 min read
Press Releases

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

December 17, 2025
·
5 min read
Press Releases

insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors

December 4, 2025
·
5 min read
Collaboration

JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.

January 12, 2026
·
3 min read
·
Annalee Armstrong
Press Releases

insitro Partners with Lilly to Build First-in-Kind Machine Learning Models to Advance Small Molecule Drug Discovery

September 9, 2025
·
4 min read
Artificial intelligence

Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line.

October 9, 2024
·
2 min read
·
Tristan Manalac